Extended-release venlafaxine in relapse prevention for patients with major depressive disorder

Journal of Psychiatric Research

Volumn 38, Issue 3, 2004, Pages 249-257

  Simon, Jeffrey S ^a   Aguiar, Loren M ^b   Kunz, Nadia R ^b   Lei, Dean ^b  

^a Northbrooke Research Center   (United States)

^b PFIZER INC   (United States)

Author keywords

Antidepressant; Depression; MDD; Prevention; Relapse; Venlafaxine

Indexed keywords

VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM; SURVIVAL; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME;

EID: 1542375433     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2003.10.004     Document Type: Article

References (45)

1. ™. 4th ed. 1994;American Psychiatric Association, Washington, DC.
2. DeBattista C., Schatzberg A.F. New options in pharmacotherapy for geriatric depression. limiting side effects and drug interactions Clin Geriatr. 4:1996;29-43.
3. Depression Guideline Panel. Clinical practice guideline number 5: depression in primary care. Vol. 2: treatment of major depression. AHCPR publication No. 93-0551. Rockville, Md: US Department of Health and Human Services, Agency for Health Care Policy and Research;1993.
4. Dierick M. An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry. 8:1996;169-178.
5. Doogan D.P., Caillard V. Sertraline in the prevention of depression. Br J Psychiatry. 160:1992;217-222.
6. Ellison L.F., Morrison H.I. Low serum cholesterol concentration and risk of suicide. Epidemiol. 12:2001;168-172.
7. Entsuah A.R., Rudolph R.L., Chitra R. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients. a meta-analysis Psychopharmacol Bull. 31:1995;759-766.
8. Entsuah A.R., Rudolph R.L., Hackett D., Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression. a pooled analysis of relapse rates Int Clin Psychopharmacol. 11:1996;137-145.
9. Feiger A.D., Bielski R.J., Bremner J., Heiser J.F., Trivedi M., Wilcox C.S.et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol. 14:1999;19-28.
10. Feighner J.P., Entsuah A.R., McPherson M.K. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord. 47:1998;55-62.
11. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E.et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 361:2003;653-661.
12. Greenhouse J.B., Stangl D., Kupfer D.J., Prien R.F. Methodologic issues in maintenance therapy clinical trials. Arch Gen Psychiatry. 48:1991;313-318.
13. Guelfi J.D., White C., Hackett D., Guichoux J.Y., Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 56:1995;450-458.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised, 1976.
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
16. Hirschfeld R.M.A. Antidepressants in long-term therapy. a review of tricyclic antidepressants and selective serotonin reuptake inhibitors Acta Psychiatr Scand. 101(403):2000;35-38.
17. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
18. Keller M.B. The long-term treatment of depression. J Clin Psychiatry. 60(17):1999;41-45.
19. Kupfer D.J. Long-term treatment of depression. J Clin Psychiatry. 52(5):1991;28-34.
20. Lecrubier Y., Bourin M., Moon C.A.L., Schifano F., Blanchard C., Danjou P.et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand. 95:1997;485-493.
21. Loonen A.J.M., Peer P.G.M., Zwanikken G.J. Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. PharmWeekbl Sci. 13:1991;167-175.
22. Ludman E., Von Korff M., Katon W., Lin E., Simon G., Walker E.et al. The design, implementation, and acceptance of a primary care-based intervention to prevent depression relapse. Int J Psychiatry Med. 30:2000;229-245.
23. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:1979;382-389.
24. Montgomery S.A., Bebbington P., Cowen P., Deakin W., Freeling P., Hallstrom C.et al. Guidelines for treating depressive illness with antidepressants : a statement from the British Association for Psychopharmacology. J Psychopharmacol. 7:1993;19-23.
25. Montgomery S.A., Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 8:1993;189-195.
26. Montgomery S.A., Roberts A., Patel A.G. Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacol. 9(1):1994;49-53.
27. Nierenberg A.A., Feighner J.P., Rudolph R., Cole J.O., Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 14:1994;419-423.
28. Partonen T., Haukka J., Virtamo J.et al. Association of low serum total cholesterol with major depression and suicide. Br J Psychiatry. 175:1999;259-262.
29. Prien R.F., Kupfer D.J. Continuation drug therapy for major depressive episodes. how long should it be maintained? Am J Psychiatry. 143:1986;18-23.
30. Rabe-Jablonska J., Poprawska I. Levels of serum total cholesterol and LDL-cholesterol in patients with major depression in acute period and remission. Med Sci Monit. 6:2000;539-547.
31. Redrobe J.P., Bourin M., Colombel M.C., Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacol. 138:1998;1-8.
32. Rudolph R.L., Derivan A.T. The safety and tolerability of venlafaxine hydrochloride. analysis of the clinical trials database J Clin Psychopharmacol. 16(3):1996;54S-61S.
33. Rudolph R.L., Feiger A.D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 56:1999;171-181.
34. Schreter R.K. Managed care cost containment strategies and their impact on physician prescribing and treatment of depression. Am J Managed Care. 6(2):2000;S47-S52,S69-S72.
35. Schweitzer I., Burrows G., Tuckwell V., Polonowita A., Flynn P., George T.et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol. 21:2001;185-189.
36. Shrivastava R.K., Cohn C., Crowder J., Davidson J., Dunner D., Feighner J.et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol. 14:1994;322-329.
37. Silverstone P.H., Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry. 60:1999;22-28.
38. Simon G.E., VonKorff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med. 4:1995;99-105.
39. Solomon D.A., Bauer M.S. Continuation and maintenance pharmacotherapy for unipolar and bipolar mood disorders. Psychiatr Clin North Am. 16:1993;515-540.
40. Storosum J.G., van Zwieten B.J., Vermeulen H.D.B., Wohlfarth T., van den Brink W. Relapse and recurrence prevention in major depression. a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues Eur Psychiatry. 16:2001;327-335.
41. Terao T., Iwata N., Kanazawa K.et al. Low serum cholesterol levels and depressive state in human dock visitors. Acta Psychiatr Scand. 101:2000;231-234.
42. Thase M.E. Defining remission in patients treated with antidepressants. J Clin Psychiatry. 60(22):1999;3-6.
43. Thase M.E. for the Venlafaxine XR 209 Study Group Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry. 58:1997;393-398.
44. Van Houdenhove B., Onghena P., Floris M., Janssen F., De Nayer A.R., Boxus A.et al. An open study of sertraline in acute and continuation treatment of depressed out-patients. J Int Med Res. 25:1997;340-353.
45. Walters G., Reynolds C.F. III., Mulsant B.H., Pollock B.G. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. J Clin Psychiatry. 60(20):1999;21-25.